Introducing the Rice Nexus. Rendering courtesy of Rice University

Rice University is going beyond the hedges with its hub at the Ion, for which the school has just details and renderings.

For over a year, Rice has been planning its Rice Nexus, a collaborative hub for the university's innovation efforts located in the Ion District, Rice Management Company's 16-acre district in Midtown. Expected to open this fall, the new space will be located across 10,000 square feet on two floors of the Ion.

“We believe in the power of innovation to transform lives and shape the future,” Rice President Reginald DesRoches says in a news release. “With the launch of the Rice Nexus at the Ion, we are embarking on a journey to unleash the full potential of Houston’s innovation ecosystem, driving positive change and rapid economic growth.”

Rendering courtesy of Rice University

The Rice Nexus will provide the university's community with prototyping tools, access to venture capital opportunities, and entrepreneurial support.

“We are thrilled to introduce the Nexus so that our faculty and students can rapidly develop, derisk and deploy solutions into the world by harnessing the full resources and capabilities of the Ion District,” Paul Cherukuri, Rice’s chief innovation officer, adds. “Houston is a grand city of innovation, and the Nexus at the Ion further amplifies Rice as a global leader in inventing and commercializing world-changing technology at both speed and scale.”

Rice reports that three startups founded by faculty — Solidec, Coflux Purification, and DirectH2 — will be located in the facility.

“The critical support provided through the Nexus highlights Rice’s leadership in pioneering essential hard tech development in the middle of the world’s energy capital, revolutionizing the country’s next-generation clean energy and chemical manufacturing technologies while fostering the next generation of innovators in energy sustainability,” says DirectH2 Co-Founder Aditya Mohite, professor of chemical and biomolecular engineering, electrical and computer engineering and materials science and nanoengineering.

Rendering courtesy of Rice University

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.